Table 4.

List of approved drugs targeting immune checkpoints for gastrointestinal cancers

Target	Drug	Commercial name	Indication
PD-1	Nivolumab	Opdivo	Hepatocellular carcinoma, colorectal cancer with MSI-H
PD-1	Pembrolizumab	Keytruda	Gastric cancer, hepatocellular carcinoma, colorectal cancer, solid tumors with MSI-H
CTLA-4 and PD-1	Ipilimumab plus nivolumab	Yervoy plus Opdivo	Colorectal cancer with MSI-H

PD-1: Programmed death 1; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; MSI-H: High microsatellite instability.